Most traditional biotech funding sources haven't made an explicit move towards investing in longevity projects. While there is a new crop of longevity-specific VCs, it's a small group. To fill the funding gap, some new and creative avenues have opened up like equity crowd funding and crypto. This panel will explore the various options available to funding aging-research and commercialization.
View the full recording here.